Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 239-938-2 | CAS number: 15834-05-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Hypothesis for the analogue approach: This read-across is based on the hypothesis that source and target substances have similar toxicological properties because, following oral intake, the source substances hydrolyse in the gut to non-common products predicted to have no toxicological effect (metabolic approach). The target substance is n-nonanoic acid, a saturated linear, medium-chain length carboxylic acid. The prediction is limited for saturated linear, medium-chain length carboxylic acids as source substances and for systemic toxicity endpoints, e.g. repeated dose toxicity and toxicity to reproduction. The prediction is supported by valid toxicological data on the substances and their hydrolysis products, based on known rapid and extensive hydrolysis and subsequent metabolism. For read across justification, see the atteched file in endpoint 13 ( Analogue approach justification): Acceptable, well-documented publication which meets basic scientific principles
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- yes
- Remarks:
- 2 doses tested
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- medium chain triglycerides
- IUPAC Name:
- medium chain triglycerides
- Details on test material:
- - Name of test material (as cited in study report): Medium Chain Triglycerides (MCT)
- Test article: a 20% lipid emulsion containing a 3:1ratio of MCT:LCT from soy bean oil
- Molecular weight: the 20% lipid emulsion is composed primarily of 8- and 10-carbon fatty acids and a trace of 6- and 12-carbon fatty acids.
- Substance type: triglycerides
- Physical state: emulsion
- Stability of test material: analytically determined to be stable
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD BR
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Portage, MI, USA
- Age at study initiation: no data
- Weight at study initiation: 150 to 200g
- Housing: singly
- Diet: ad libitum except during dose administration
- Water: ad libitum except during dose administration
- Acclimation period: 2
ENVIRONMENTAL CONDITIONS
air-conditioned rooms
Administration / exposure
- Route of administration:
- other: intravenous infusion (caudal vein)
- Vehicle:
- soya oil
- Details on exposure:
- VEHICLE
- Justification for use and choice of vehicle (if other than water): for reasons of solubility
- Concentration in vehicle: 3.1 ratio of MCT:LCT from soya oil - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Stability was analytically determined which implies analytical verification of composition and doses. Methods were not described.
- Details on mating procedure:
- Time-mated animals; no further details described.
- Duration of treatment / exposure:
- GD 6 through 15
- Frequency of treatment:
- daily
- Duration of test:
- until GD 20
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 1, and 4.28 g/kg bw and day
Basis:
other: i.v. dose
- No. of animals per sex per dose:
- 25
- Control animals:
- yes, sham-exposed
- Details on study design:
- - Dose selection rationale: 4.28% was the highest dose in preclinical studies that did not produce narcosis
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least daily
BODY WEIGHT: Yes
- Time schedule for examinations: pre-dose and on GD5 through GD20
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): n. a.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): n.a.
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day #20 - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: No data - Statistics:
- The litter was the experimental unit for evaluation and all comparisons were made with the control group. Amongst other calculations, ANOVA followed by Dunnett's test was used to analyse body weights, feed consumption, caesarian section data. Foetal abnormality data were analysed using the Cochran.-Armitage test and the Fisher-Irwin exact test.
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
Tail lesions such as discoloration and ulceration were seen in treated groups (incidences 1/25, 14/25, and 23/29 in the control low- and high-dose groups, respectively. Findings ranged from mild to severe with some necrosis and partial tail loss. This was related to extravasation of the lipid test article.
Body weight was comparable between controls and low-dose animals; reduced body weight and feed consumption was noted in high-dose rats. After cessation of treatment, feed consumption increased. Necropsy revealed tail effects in the low dose group and especially in the high dose animals. . Further, there was a trend in the high-dose group, towards enlarged lymph nodes, enlarged spleen, hydronephrosis/enlarged renal pelvis, small thymus, and small red lung foci. See table below for further details.
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 4 280 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Dose descriptor:
- NOAEL
- Effect level:
- 1 820 mg/kg bw/day (actual dose received)
- Based on:
- other: estimated NOAEL for octa- and decanoic acid. Read acorss: also of nonanoic acid
- Basis for effect level:
- other: developmental toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
There were no significant group differences in preimplantation or postimplantation loss or in the mean percentage of live or resorbed foetuses; no dead foetuses were present. Mean foetal sex ratios of the test article-treated groups were comparable with those of controls. There were no apparent effects on mean foetal body weight (combined, males, or females). Finally, there were no test article-related foetal external, soft tissue, or skeletal observations.
Effect levels (fetuses)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 4 280 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: teratogenicity
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1 820 mg/kg bw/day (actual dose received)
- Based on:
- other: estimated NOAEL for octa- and decanoic acid. Read acorss: also of nonanoic acid
- Basis for effect level:
- other: teratogenicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
Applicant's summary and conclusion
- Conclusions:
- Intravenous doses of MCT (up to 4280 mg/kg bw and day, GD 5-20) caused maternal effects at the high dose, but no developmental toxicity or teratogenicity. The NOAEL was therefore 1000 mg/kg bw and day for maternal toxicity and 4280 mg/kg bw and day for developmental toxicity and teratogenicity.
- Executive summary:
Time-mated rats (25/group) received intravenous infusions into the caudal vein (duration 4h/day) during gestation Days 6 through 15 of a 20% lipid emulsion that contained a ratio of 3:1 of MCT and Long Chain Triglycerids (LCT) from soy bean oil at doses of 1 and 4.28 g/kg bw and day. Controls received 0.9% saline). Medium chain fatty acids are 6 to 12 carbons in length. The 20% lipid emulsion is composed primarily of 8- and 10-carbon fatty acids, with traces of 6- and 12-carbon fatty acids. The dams were observed for clinical signs and sacrificed at termination. Examinations of the dams and of the uterus content were performed.
No clinical signs or mortalities were noted. Changes in high-dose rats (enlarged lymph nodes, spleen, and renal pelvis; small thymus, small red lung foci) were considered to be related to treatment, hence the NOAEL was 1 000 mg/kg bw and day for maternal toxicity. As to the foetuses, there were no significant differences compared to controls regarding early or late resorptions, post implantation loss, dead or alive foetuses, mean uterine weight and foetal weight (though there was a trend towards lower weights at the high dose), and there were no external, soft tissue or skeletal changes that could be related to treatment. Hence, the NOAEL for developmental toxicity and teratogenicity was 4280 mg/kg bw and day (Henwood et al., 1997).
The study is considered to be valid. The intravenous route was used because the parenteral route is used in patients that cannot meet their nutritional needs by the conventional oral route, and 1000 mg/kg bw and day is the approximate clinical dose, whereas 4280 mg/kg bw and day is reportedly the highest preclinical dose that did not cause narcosis.
The study can be used for the assessment of n-nonanoic acid in a way as this has been described in the repeated dose toxicity section for the studies of Matulka and Webb who also administered triglycerides as test material. In brief,
- the metabolism of straight chain fatty acids of 8 to 10 carbons including nonanoic acid is very similar and includes rapid degradation via ß-oxidation, which justifies cross reading form C8 and C10-fatty acids to C9 nonanoic acid.
- The fatty acid composition of the test material of this study (Henwood et al., 1997) was almost exclusively C8 and C10, with traces of C6 and C12.
- The mean molecular weight of the triglycerides is calculated assuming that traces are negligible, and that C8 and C10 are present in equimolar proportions (this was not specified in the publication). Then, the mean triglyceride molecular weight is 596, and the two fatty acids represent 42.5% each of the molecular weight, and also the dose, i.e. approx. 1820 mg of C8 and also of C10 fatty acid/kg bw and dose.
In a weight of evidence approach, this result can be used to assess n-nonanoic acid: NOAEL approx.. 1820 mg/kg bw and day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.